Vanda Pharmaceuticals (VNDA) closed at $4.00 on October 28, 2026, up 0.3% from the previous close, on volume of 1,827,012 shares (30-day average 1,042,450).
Data as of October 28, 2026.
Vanda Pharmaceuticals GAAP EPS of -$0.37 beats by $0.31, revenue of $69.82M beats by $0.7M
Seeking Alpha News (Wed, 28-Oct 4:29 PM ET)
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
PRNewswire (Wed, 28-Oct 4:01 PM ET)
Vanda Pharmaceuticals Q3 Earnings Preview
Seeking Alpha News (Tue, 27-Oct 5:35 PM ET)
PRNewswire (Tue, 27-Oct 6:50 AM ET)
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
PRNewswire (Wed, 21-Oct 5:41 PM ET)
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
PRNewswire (Wed, 14-Oct 5:01 PM ET)
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
PRNewswire (Fri, 2-Oct 9:07 AM ET)
VNDA spotlights Phase III HETLIOZ data: 37.1-minute sleep-onset improvement versus placebo in DSWPD
Market Chameleon (Wed, 30-Sep 3:06 AM ET)
PRNewswire (Tue, 29-Sep 6:46 PM ET)
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
PRNewswire (Wed, 2-Sep 4:52 PM ET)
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Vanda Pharmaceuticals trades on the NASDAQ stock market under the symbol VNDA.
As of October 28, 2026, VNDA stock price climbed to $4.00 with 1,827,012 million shares trading.
VNDA has a beta of 0.59, meaning it tends to be less sensitive to market movements. VNDA has a correlation of 0.01 to the broad based SPY ETF.
VNDA has a market cap of $240.54 million. This is considered a Small Cap stock.
Last quarter Vanda Pharmaceuticals reported $51 million in Revenue and -$1.04 earnings per share. This fell short of revenue expectation by $-12 million and missed earnings estimates by -$.47.
In the last 3 years, VNDA traded as high as $9.94 and as low as $3.30.
The top ETF exchange traded funds that VNDA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
VNDA has underperformed the market in the last year with a price return of -28.7% while the SPY ETF gained +13.8%. VNDA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.4% and -7.0%, respectively, while the SPY returned +4.8% and -0.7%, respectively.
VNDA support price is $3.87 and resistance is $4.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNDA shares will trade within this expected range on the day.
